PATH strikes more pneumococcal vaccine alliances
This article was originally published in Scrip
PATH (the Program for Appropriate Technology in Health) has struck several new alliances under its project to develop and make available in developing countries affordable new vaccines offering broad protection against pneumococcal infections.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Japan’s largest pharma company says it has seen no impact on its financial results so far from the coronavirus pandemic, with continuing growth for mainstay drugs, and raises its profit forecasts for the fiscal year on favorable one-off factors.
Roche’s Japanese affiliate says the impact of the pandemic on its second quarter was limited, but points to a more uncertain outlook for the rest of the year, during which it vows to keep focusing on innovation.